L'intérêt à découvert pour Soleno Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Soleno Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Soleno Therapeutics (NASDAQ:SLNO) Stock, Rapport sur les intérêts à découvert

SOLENO THERAPEUTICS INC

Soleno Therapeutics

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

Soleno Therapeutics Inc

WIIM

NMTC

NeuroOne Medical Technologies shares are trading lower after the company commenced a common stock public offering.

CXAI

CXApp shares are trading higher after the company reported business performance results for 2024 and announced a net revenue retention rate of 101%.

News

Management

TBBK

Paul Frenkiel Retires As CFO Of The Bancorp, Martin Egan Appointed Interim CFO

Guidance

LFCR

Lifecore Biomedical Reiterates FY25 Revenue ~$126.5M-$130M Vs $128.439M Est.

Earnings

Earnings Beats

General

Simulations Plus Sees FY25 Adj. EPS $1.07-$1.20 Vs $0.47 Est; Revenue $90M-$93M Vs $90.445M Est

Lifecore Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.15) by 213.33 percent. This is a 217.5 percent decrease over earnings of $0.40 per share from the same period last year. The company reported quarterly sales of $35.154 million which beat the analyst consensus estimate of $33.229 million by 5.79 percent. This is a 1.54 percent decrease over sales of $35.704 million the same period last year.

Earnings Misses

Lifecore Biomedical Q3 2025 GAAP EPS $(0.47) Misses $(0.15) Estimate, Sales $35.154M Beat $33.229M Estimate

Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) reported quarterly losses of $(52.80) per share. This is a 77.24 percent increase over losses of $(231.99) per share from the same period last year.

APLM

Apollomics FY24 EPS $(52.80) Up From $(231.99) YoY

SGMO

Sangamo Therapeutics shares are trading higher after the company announced it entered a capsid license agreement with Lilly.

Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) shares traded lower on Thursday as broader markets reacted to President Donald Trump's <a href="https://www.benzinga.com/markets/25/04/44621408/market-access-has-a-price-trump-unveils-list-of-tariffs-countries-targeted">sweeping tariff plan.</a>
What To Know: The Trump administration announced reciprocal tariffs on several countries on Wednesday. Trump invoked the International Emergency Economic Powers Act to justify the tariffs, citing a $1.2 trillion trade deficit in 2024 and arguing that prior administrations failed to address what he calls unfair trade practices. 
The new measures include specific tariff rates on major trade partners. The policy changes have drawn swift condemnation from global leaders and are expected to prompt retaliatory measures, which could further pressure global markets.
Markets reacted negatively to the announcement, with major indexes facing declines of as much as 6%. Analysts warn that the tariffs could fuel inflation, increase costs for U.S. consumers and heighten recession risks. 
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44632659/trump-tariffs-could-blow-up-apple-analyst-estimates-39-5-billion-impact">&#8216;Trump Tariffs Could Blow Up Apple&#8217;: Analyst Estimates $39.5 Billion Impact</a>
Investors are also concerned about potential countermeasures from targeted countries, which could further disrupt global trade and impact multinational companies like Meta, which relies on international markets for advertising revenue and data infrastructure.
Meta's decline reflects the broader market sell-off, with investors reassessing the impact of escalating trade tensions on technology and communication firms. Investors fear that increased tariffs could impact digital advertising spending. Furthermore, if retaliatory tariffs target digital services or data-related businesses, companies like Meta could face additional pressure.
META Price Action: <a href="http://benzinga.com/quote/meta">Meta shares</a> closed Thursday down 8.96% at $531.62, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44631916/wall-street-wipes-out-2-trillion-apple-eyes-worst-day-since-covid-19-pandemic-oil-plummets-whats-driving-markets-thursday">Wall Street Wipes Out $2 Trillion, Apple Eyes Worst Day Since COVID-19 Pandemic, Oil Plummets: What&#8217;s Driving Markets Thursday?</a></li>
</ul>
Image via Shutterstock.

Movers

Meta Stock Drops 9% Thursday As Tariff Fears Shake Tech Sector: What You Need To Know

Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.12 by 158.33 percent. This is a 55 percent increase over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $22.400 million which beat the analyst consensus estimate of $21.925 million by 2.17 percent. This is a 22.37 percent increase over sales of $18.305 million the same period last year.

Simulations Plus Q2 2025 Adj. EPS $0.31 Beats $0.12 Estimate, Sales $22.400M Beat $21.925M Estimate

NeuroOne Medical Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) (the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has commenced a proposed underwritten registered public offering of shares of its common stock.
All of the shares of common stock to be sold in the proposed offering will be sold by the Company. In addition, the Company intends to grant the underwriter a 45-day option to purchase up to an additional 15% of the shares of its common stock sold in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Ladenburg Thalmann &amp; Co. Inc. is acting as sole book-running manager for the proposed offering.
The proposed offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-279871) that was declared effective by the U.S. Securities and Exchange Commission ("SEC"), on August 16, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available on the SEC's website at <a href="https://www.globenewswire.com/Tracker?data=ZjT7OhPMpMZEFABBLL7l1sDyYnNgNm6qKoJoQcsGudsGHPaI4wQguKQ86QG0t_uxJAqJNGo3VzU0pOw17K8DEg==">www.sec.gov</a> or by contacting Ladenburg Thalmann &amp; Co. Inc., 640 Fifth Avenue, 4th Floor, New York, New York 10019, or by telephone at (212) 409-2000 or by email at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=FL7656NfbTjDF7g7S0eRL_E6XZ46Gos1Yw2nXpwdKjbii2-JTEDzULGkXQOWAZdhtub2Oq2Nihk-xIeL1dKj5uI9yh_8r2T3P6M-45Em9AtrYlP61pooI1CZ6EyX3OqO">prospectus@ladenburg.com</a>.&nbsp;
This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

Biotech

Offerings

Neuroone Medical Technologies Commences A Proposed Underwritten Registered Public Offering Of Shares Of Its Common Stock

Major corporations have already begun announcing layoffs on Thursday as President Donald Trump's sweeping new tariff structure is <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44630499/trump-auto-tariffs-could-up-car-prices-by-15k-analyst-calls-it-pure-chaos">set to take effect.&nbsp;</a>
What To Know: One of the Big Three automakers, Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>), said on Thursday that it will be temporarily laying off 900 workers and pausing production at one assembly plant each in Mexico and Canada.&nbsp;
The move comes after a 25% tariff on all imported vehicles and auto parts went into effect on Thursday. Meanwhile, President Trump introduced a base 10% tariff on all goods coming into the United States and a broad set of reciprocal tariffs targeting several countries on Wednesday. 
Read Next:<a href="https://www.benzinga.com/government/regulations/25/03/44517885/trump-slaps-25-tariffs-on-autos-what-it-means-for-your-next-car-purchase"> Trump Slaps 25% Tariffs On Autos: What It Means For Your Next Car Purchase</a>&nbsp;
According to a Reuters report, Stellantis' Windsor Assembly in Canada will be down for two weeks while Toluca Assembly in Mexico, will be down for the month of April.&nbsp;
About 4,500 workers at Windsor will be impacted by the shutdown, while workers at Toluca will continue to report to work and get paid but will not make vehicles.&nbsp;
Stellantis COO Antonio Filosa said the company is &#8220;continuing to assess the medium- and long-term effects of these tariffs on our operations, but also have decided to take some immediate action,&#8221; in a letter sent to employees Thursday morning.&nbsp;
U.S. Senate Minority Leader Chuck Schumer called the job cuts at Stellantis "a horrifying consequence of Trump's tariffs" in a social media post. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">A horrifying consequence of Trump's tariffs. American workers are paying the price. <a href="https://t.co/D8ndd9Wbzi">https://t.co/D8ndd9Wbzi</a>
&mdash; Chuck Schumer (@SenSchumer) <a href="https://twitter.com/SenSchumer/status/1907852130452455723?ref_src=twsrc%5Etfw">April 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
More Cuts: Whirlpool Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) announced on Thursday that it will lay off 651 workers from its manufacturing facility in Amana, Iowa, effective June 1. 
The company released a statement blaming the workforce reduction on slowing consumer demand.&nbsp;
"This is really about aligning to current market conditions driven by consumer demand, particularly as it relates to some of the appliances (refrigeration) made in Amana," Whirlpool's statement said.
Fisher-Price, a subsidiary of Mattel, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>), also laid off up to 15 employees at its headquarters in East Aurora, New York on Thursday, according to<a href="https://buffalonews.com/news/local/business/article_9a3bfd49-4e15-40e5-843f-9ba3afcbd7e3.html"> a report</a> from the Buffalo News.&nbsp;
The company did not confirm the number of affected employees, but a Mattel spokesperson said the cuts are in line with the company&#8217;s Optimizing for Profitable Growth cost savings program.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/global/25/04/44628368/trumps-tariffs-prompt-china-to-vow-countermeasures-experts-see-retaliation-likely">Trump&#8217;s Tariffs Prompt China To Vow &#8216;Countermeasures&#8217;: Experts See Retaliation Likely&nbsp;</a></li>
</ul>
Image: Shutterstock

Politics

Global

Economics

STLA

'Horrifying Consequence Of Trump's Tariffs': Schumer Blames Trump Tariffs For Stellantis Layoffs

I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) reported quarterly losses of $(0.27) per share. This is a 89.2 percent increase over losses of $(2.50) per share from the same period last year.

IMAB

I-MAB FY24 Adj EPADS $(0.27) Up From $(2.50) YoY

CXApp FY24 Net Revenue Retention 101%

5 analysts have shared their evaluations of HF Sinclair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DINO#NYSE">DINO</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $41.2, along with a high estimate of $50.00 and a low estimate of $35.00. Observing a downward trend, the current average is 5.07% lower than the prior average price target of $43.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1743710577_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of HF Sinclair among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$44.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$35.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$37.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to HF Sinclair. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of HF Sinclair compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of HF Sinclair's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DINO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on HF Sinclair analyst ratings.</a>
<h2>Delving into HF Sinclair's Background</h2>
HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 300 distributors and 1,500 wholesale branded sites across 30 states. It also owns and operates 4,400 miles of petroleum product pipelines and terminals principally in the southwestern United States.
<h3>Financial Milestones: HF Sinclair's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining HF Sinclair's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -15.14% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: HF Sinclair's net margin is impressive, surpassing industry averages. With a net margin of -3.28%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -2.26%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): HF Sinclair's ROA excels beyond industry benchmarks, reaching -1.27%. This signifies efficient management of assets and strong financial health.
Debt Management: HF Sinclair's debt-to-equity ratio is below the industry average. With a ratio of 0.33, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

DINO

What Analysts Are Saying About HF Sinclair Stock

Sangamo Therapeutics Enters Capsid License Agreement With Lilly; To Receive $18M Upfront License Fee And Is Eligible To Earn Up To $1.4B In Additional Licensed Target Fees And Milestone Payments

12 analysts have shared their evaluations of Raymond James Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $174.08, a high estimate of $201.00, and a low estimate of $150.00. This upward trend is apparent, with the current average reflecting a 2.9% increase from the previous average price target of $169.17.
<img src="https://www.benzinga.com/files/images/story/2025/1743710538_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Raymond James Finl among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$173.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$161.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Mark McLaughlin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$201.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Michael Cho</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$172.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$177.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$190.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$176.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$168.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Michael Cho</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$166.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$161.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Raymond James Finl. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Raymond James Finl compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Raymond James Finl's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Raymond James Finl's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RJF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Raymond James Finl analyst ratings.</a>
<h2>Unveiling the Story Behind Raymond James Finl</h2>
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company supports more than 8,000 employee and independent contractor financial advisors across the United States, Canada, and the United Kingdom with over $1.5 trillion of assets under administration as of September 2024. Approximately 90% of the company's revenue is from the US and 70% is from the company's wealth-management segment.
<h3>Breaking Down Raymond James Finl's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Raymond James Finl's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 17.19%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Raymond James Finl's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 17.19%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Raymond James Finl's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 5.11%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Raymond James Finl's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.72%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Raymond James Finl's debt-to-equity ratio is below the industry average. With a ratio of 0.26, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Raymond James Finl Stock

In the last three months, 7 analysts have published ratings on Stifel Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SF#NYSE">SF</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $120.43, a high estimate of $135.00, and a low estimate of $105.00. A 1.4% drop is evident in the current average compared to the previous average price target of $122.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1743710512_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Stifel Financial among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$135.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$128.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Stifel Financial. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Stifel Financial compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Stifel Financial's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Stifel Financial's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Stifel Financial analyst ratings.</a>
<h2>About Stifel Financial</h2>
Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.
<h3>Breaking Down Stifel Financial's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Stifel Financial's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 19.21%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Stifel Financial's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 17.41%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Stifel Financial's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 4.75%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Stifel Financial's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.6%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.31, Stifel Financial adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Stifel Financial Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.perion.com%2F&amp;esheet=54233165&amp;newsitemid=20250403072976&amp;lan=en-US&amp;anchor=Perion+Network+Ltd&amp;index=1&amp;md5=97b37121d9ff25cab98b322e8f198d95">Perion Network Ltd</a>. (NASDAQ and TASE: PERI), a leader in advanced technology solving for the complexities of modern advertising, announced today that its Board of Directors adopted a limited duration shareholder rights plan (the "Rights Plan").
The Rights Plan is intended to enable Perion's shareholders to realize the full potential value of their investment. It is designed to reduce the likelihood that any entity, person or group would gain control of, or significant influence over Perion through open-market transactions or other means for accumulation of the Company's shares without appropriately compensating all of Perion's shareholders or providing the Board sufficient time to make informed, strategic decisions in the best interests of the Company and its shareholders.
Perion's management and Board of Directors believe the Company's current share price does not reflect its intrinsic value and its long-term growth strategy and potential. Participants in the AdTech ecosystem with deep knowledge and understanding of the Company's technology, offerings, and talent, may view the Company as an attractive acquisition target. The adoption of the Rights Plan is intended to prevent such parties from opportunistically gaining control of the Company at an undervalued price without fairly compensating all shareholders.
The Rights Plan is not intended to prevent or interfere with any action with respect to Perion that the Board determines to be in the best interests of the Company and its shareholders. Rather, it will position the Board to fulfill its fiduciary duties to all shareholders by ensuring it can properly assess any efforts or attempts to gain control or significant influence over the company. The Rights Plan is designed to encourage anyone interested in Perion to engage with the Board and management constructively and transparently and to do so in a manner that appropriately reflects the Company's intrinsic value. Perion's Board and management remain fully committed to acting in all shareholders' best interests and executing Perion's long-term growth strategy to deliver sustained shareholder value.
The Rights Plan is similar to those adopted by other publicly traded companies. Pursuant to the Rights Plan, Perion will issue one right for each ordinary share outstanding as of the close of business on April 14, 2025. While the Rights Plan is effective immediately, the rights generally would become exercisable only if an entity, person or group acquires beneficial ownership of 13% or more of Perion's outstanding ordinary shares in a transaction not approved by the Company's Board.
In that situation, each holder of a right (other than the acquiring entity, person or group) would have the right to purchase 0.5 ordinary shares at a purchase price of $0.01 per share. In addition, at any time after an entity, person or group acquires 13% or more of Perion's ordinary shares, the Company's Board of Directors may exchange 0.5 ordinary shares of the Company for each outstanding right (other than rights owned by such entity, person or group which has triggered the Rights Plan, which would have become void).
The Rights Plan will expire on April 2, 2026, or earlier as provided in the Rights Plan.

PERI

Perion Network Announces It Has Adopted A Limited Duration Shareholder Rights Plan

Ratings for Victory Capital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCTR#NASDAQ">VCTR</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $73.83, a high estimate of $87.00, and a low estimate of $60.00. This current average has increased by 5.47% from the previous average price target of $70.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1743710492_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Victory Capital Holdings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$87.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$69.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Etienne Ricard</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Matt Howlett</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$57.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Victory Capital Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Victory Capital Holdings compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Victory Capital Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Victory Capital Holdings's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VCTR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Victory Capital Holdings analyst ratings.</a>
<h2>Unveiling the Story Behind Victory Capital Holdings</h2>
Victory Capital Holdings Inc is an independent investment management firm. The company operates its business through franchises and solutions platform. It provides centralized distribution, marketing, and operations infrastructure to the company's franchises and solutions platform. The company operates through one business segment that is Investment management services and products to institutional, intermediary, retirement platforms, and individual investors. The franchises and solutions platform manages a variety of investment strategies for its customers. It derives majority of its revenues from asset-based fees from investment management products and services to individuals and institutions.
<h3>Financial Milestones: Victory Capital Holdings's Journey</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Victory Capital Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 12.91% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Victory Capital Holdings's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 33.11%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Victory Capital Holdings's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.7% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Victory Capital Holdings's ROA excels beyond industry benchmarks, reaching 2.98%. This signifies efficient management of assets and strong financial health.
Debt Management: Victory Capital Holdings's debt-to-equity ratio is below the industry average at 0.86, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VCTR

Deep Dive Into Victory Capital Holdings Stock: Analyst Perspectives (6 Ratings)

Press Releases

Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.

Soleno Therapeutics to Participate in Upcoming November Investor Conferences

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Health Care

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024

Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Financing

Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC

Soleno Therapeutics to Participate in Upcoming February Investor Conferences

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

Comments

Soleno Therapeutics

Intérêt court

Soleno Therapeutics (NASDAQ:SLNO) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL